Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse FDA Decision: GRI Bio, Inc. (GRI)

The Phase 3 date for Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse by GRI Bio, Inc. (GRI) is scheduled for November 1, 2037. This is the target date for the FDA to make a decision on this application.

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse is being developed by GRI Bio, Inc. for the treatment of its target indication. It is currently in Phase 3 clinical trials.

If Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse receives FDA approval, GRI Bio, Inc. (GRI) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 3 date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for GRI on DilutionWatch at dilutionwatch.com/stock/GRI.html.

You can view the full BiotechSigns company profile for GRI Bio, Inc. (GRI) at biotechsign.com/app/company/GRI, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.